Article
Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions.
Molecular cancer therapeutics - 1 May 2018
Floc'h Nicolas, Martin Matthew J, Riess Jonathan W, Orme Jonathan P, Staniszewska Anna D, Ménard Ludovic, Cuomo Maria Emanuela, O'Neill Daniel J, Ward Richard A, Finlay M Raymond V, McKerrecher Darren, Cheng Mingshan, Vang Daniel P, Burich Rebekah A, Keck James G, Gandara David R, Mack Philip C, Cross Darren A E
Abstract excerpt
EGFR exon 20 insertions (Ex20Ins) account for 4% to 10% of EGFR activating mutations in non-small cell lung cancer (NSCLC). EGFR Ex20Ins tumors are generally unresponsive to first- and second-generation EGFR inhibitors, and current standard of care for NSCLC patients with EGFR Ex20Ins is conventional cytotoxic chemotherapy. Therefore, the development of an EGFR TKI that can more effectively target NSCLC with EGFR...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.